Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» relapsed/refractory ovarian cancer
relapsed/refractory ovarian cancer
MaxCyte begins dosing in phase I solid tumors clinical trial
Pharmaceutical Business Review
Thu, 10/11/18 - 09:41 am
MaxCyte
MCY-M11
relapsed/refractory ovarian cancer
ovarian cancer
peritoneal mesothelioma
solid tumors
